Bismuth

From NuGOwiki

Jump to: navigation, search

The NuGOwiki Metabolite Database is a joint initiative of NuGO and HMDB

Taxonomy Navigation Box; search by

All Metabolites | Biochemical | Nutritional | Functional | Metabolic Pathways | Diseases | Phenotypes | Physiological Processes | Protein

Bismuth
2D structure for Bismuth
Chemical Name bismuth
Chemical Formula Bi
CAS Number 7440-69-9
Chemical Information HMDB02196
Biochemical Taxonomy Not Available
Functional Taxonomy Not Available
Nutritional Taxonomy

  • Minerals

Metabolic Pathways Not Available
Biofluid Location

  • Blood

Tissue Location Not Available
Normal Biofluid Concentrations

  • Blood: 0.000096 +/- 0.000048 uM

Normal Tissue Concentrations Not Available
Diseases / Conditions Related to Nutrition

  • Alzheimer's patients
  • Multiple Sclerosis
  • Parkinson's Disease

Other (Monogenic Disorders) Not Available
Abnormal Biofluid Concentrations

  • Blood (Alzheimer's patients): 0.000096 +/- 0.000048 uM
  • Blood (Multiple Sclerosis): 0.00019 +/- 0.0001 uM
  • Blood (Parkinson's Disease): 0.0000957 +/- 0.0000479 uM

Abnormal Tissue Concentrations Not Available
Physiological Processes Not Available
Authors:
Affiliations:

Contents

Introduction

guidelines
The normal concentration of bismuth in blood is between 1 and 15 ug/L, but absorption from oral preparations produces a significant rise. Distribution of bismuth in the organs is largely independent of the compound administered or the route of administration: the concentration in kidney is always highest and the substance is also retained there for a long time. It is bound to a bismuth-metal binding protein in the kidney, the synthesis of which can be induced by the metal itself. Elimination from the body takes place by the urinary and faecal routes, but the exact proportion contributed by each route is still unknown. Elimination from blood displays multicompartment pharmacokinetics, the shortest half life described in humans being 3.5 minutes, and the longest 17 to 22 years. A number of toxic effects have been attributed to bismuth compounds in humans: nephropathy, encephalopathy, osteoarthropathy, gingivitis, stomatitis and colitis. Whether hepatitis is a side effect, however, is open to dispute. Each of these adverse effects is associated with certain bismuth compounds. Bismuth encephalopathy occurred in France as an epidemic of toxicity and was associated with the intake of inorganic salts including bismuth subnitrate, subcarbonate and subgallate. In the prodromal phase patients developed problems in walking, standing or writing, deterioration of memory, changes in behaviour, insomnia and muscle cramps, together with several psychiatric symptoms.

Biological Function

guidelines

Catabolism

guidelines

Diseases / Conditions Related to Nutrition

guidelines

  • Alzheimer's patients
  • Multiple Sclerosis
  • Parkinson's Disease

Other (Monogenic) Disorders

guidelines


Nutritional Information

guidelines

Drivers for biological variation

guidelines

Vulnerable groups

guidelines

Other resources

guidelines

Links

guidelines